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MRI of Metronidazole-Induced Encephalopathy 
Hyojeong Mulcahy, M.D., and Shashi K.B. Chaddha, M.D.
We report the magnetic resonance imaging (MRI) findings of metronidazole-induced encephalop-
athy in a 58-year-old man who was treated with metronidazole for hepatic encephalopathy. MRI 
is likely to be helpful in confirming the diagnosis of metronidazole toxicity in clinically suspected 
cases.
Metronidazole (Flagyl) is a common antimicrobial 
agent used in the treatment of anaerobic and protozoal 
infections. For the patients with hepatic encephalopathy, 
metronidazole is used to remove the nitrogenous load in 
the gastrointestinal tract. Dose and duration of met-
ronidazole should be minimized as much as possible to 
avoid side effects such as peripheral neuropathy, cerebel-
lar dysfunction, and seizures [1-2]. We present a case of 
metronidazole-induced encephalopathy.
Introduction
Case Report
A 58- year-old man presented with a chief complaint 
of increasing confusion, intermittent episodes of imbal-
ance, and episodes of abnormal behavior. His medical 
history was significant for cirrhosis and hepatic enceph-
alopathy secondary to congenital hepatic fibrosis. On 
neurologic examination, he had a horizontal nystagmus, 
demonstrated dysmetria on finger-to-nose test, and 
Romberg’s sign was positive. He was on metronidazole 
500 mg, orally twice a day, at home for his hepatic 
encephalopathy, and the dose was increased during 
admission to 750 mg orally twice a day.
CT scan of the brain showed mild atrophy (not 
shown). The patient went on to further evaluation with 
MRI. MR imaging demonstrated strikingly increased 
signal intensity symmetrically involving the dentate 
nuclei bilaterally on T2-weighted and fluid-attenuated 
inversion recovery (FLAIR) images (Fig 1A & B), with 
isointensity on T1-weighted images and no evidence of 
enhancement following administration of gadolinium 
(Fig 2A & B). Diffusion weighted imaging demonstrat-
ed corresponding high signal intensity within the den-
tate nuclei on the isotropic diffusion images (Fig 3). An 
apparent diffusion coefficient (ADC) map demonstrated 
an increase in the value of the diffusion coefficients in 
the regions of diffusion signal intensity abnormality, 
consistent with T2 shine-through (not shown).
Discussion
Metronidazole (Flagyl) is a common antimicrobial 
agent used in the treatment of anaerobic and protozoal 
infections. For the patients with hepatic encephalopathy, 
metronidazole is used to remove the nitrogenous load in 
the gastrointestinal tract, and it’s generally administered 
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Figure 1. 58-year-old man with metronidazole-induced encephalopathy. Axial T2-weighted (A), and FLAIR (B) MR images 
show markedly increased signal intensity symmetrically involving the dentate nuclei bilaterally without surrounding edema or 
mass effect.
at 250 mg every 8 to 12 hours (500 to 750 mg daily) 
[3]. Dose and duration of metronidazole should be 
minimized as much as possible to avoid side effects asso-
ciated with its long-term use such as peripheral neuropa-
thy, cerebellar dysfunction, and seizures[1-2]. Although 
this phenomenon has been described as a manifesta-
tion of drug toxicity, it is not clear why metronidazole 
causes these lesions in a small number of patients, and 
cases have been reported in which the serum levels of 
metronidazole were within the therapeutic range[4]. No 
serum or cerebrospinal fluid level of metronidazole was 
obtained in our patient, and the diagnosis of metronida-
zole toxicity was made clinically and supported by the 
MR imaging findings.
Depending on their severity and chronicity, liver dis-
eases have variable neurologic manifestations, and it is 
becoming widely recognized that patients with chronic 
liver disease exhibit typical abnormalities on MRI. High 
signal intensities in the globus pallidus on T1-weighted 
images have been established as a characteristic finding 
on MR images in chronic hepatic encephalopathy, and 
recent data have shown that white matter abnormalities 
can also be detected[5,6]. However, cerebellar lesions 
have rarely been observed on MRI studies, and there 
are a few reports describing abnormal T2 high signal 
intensities in superficial and deep cerebellar white matter 
including the brachium pontis in patients with acquired 
hepatocerebral degeneration[7,8].
After Ahmed et al first described the imaging find-
ings of metronidazole toxicity[9], there are only several 
reported cases describing imaging findings of metron-
idazole toxicity in literature. Imaging abnormalities asso-
ciated with metronidazole toxicity have identified lesions 
in the dentate nuclei of the cerebellum, corpus callosum, 
basal ganglia, and frontal and subcortical white mat-
ter, and MR imaging findings of bilateral involvement 
of the dentate nuclei are a very characteristic feature of 
metronidazole-induced encephalopathy[4,9-12]. In our 
case, it was the only demonstrated lesion on MR imag-
ing.
The mechanism of metronidazole toxicity has not 
been elucidated, and the apparent preferential involve-
ment of the dentate nucleus remains puzzling. The sig-
nal intensity changes observed on the diffusion weighted 
images most likely represent interstitial edema[9,11], 
even though it could represent cytotoxic edema in le-
sions of the corpus callosum[12]. The findings on MR 
spectroscopy suggest the possibility of a reversible mito-
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Figure 2. 58-year-old man with metronidazole-induced encephalopathy. Axial pre- (A), and post-gadolinium (B) T1-weighted 
MR images show T1 isointensity and no evidence of enhancement following administration of gadolinium.
chondrial dysfunction as a cause of the abnormalities in 
susceptible patients[13]. The imaging, spectroscopy, and 
clinical findings reverse after discontinuation of metron-
idazole therapy[4,9-12].
Figure 3. 58-year-old man with metronidazole-induced 
encephalopathy. Axial isotropic diffusion-weighted MR im-
age shows corresponding high signal intensity within the 
dentate nuclei.
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